Neurology Grand Rounds

Kinne Auditorium

Monday September 25, 2017 at 12:15 PM

Video-conferenced to Nemours 1 North and Brooks Rehab

Nilufer Taner, M.D., PhD., presents:

“Systems Biology Approaches in Drug Target Discovery in Alzheimer’s Disease”

Nilüfer Ertekin-Taner, MD, PhD is a Professor of Neurology and Professor of Neuroscience at the Mayo Clinic, Jacksonville, FL, USA. She is a neurogeneticist and board-certified behavioural neurologist. Dr. Ertekin-Taner received her medical degree from Hacettepe University Medical School in Ankara, Turkey and her doctorate degree in Molecular Neuroscience from Mayo Graduate School. She completed her residency training in the Department of Neurology at Mayo Clinic in Rochester, MN and fellowship in Behavioral Neurology at Mayo Clinic in Jacksonville, FL. Dr. Ertekin-Taner’s laboratory aims to discover and characterize genetic factors underlying the complex genetics of Alzheimer’s disease (AD) and related neurodegenerative conditions. Her earlier work contributed to the establishment of the endophenotype approach in genetic studies of AD and pioneered the use of amyloid β peptide levels as an endophenotype in AD genetic research. Dr. Ertekin-Taner’s laboratory currently uses biological traits such as gene expression levels and cognitive scores and leverages combined genome, transcriptome and epigenetic data to uncover genetic risk factors for neurodegenerative conditions. Dr. Ertekin-Taner is the Principal Investigator (PI) of numerous NIH and foundation grants. She leads multiple collaborative projects aimed at gene and pathway discoveries in AD and other neurodegenerative diseases, as part of the NIH initiatives Accelerating Medicines Partnership Alzheimer’s Disease (AMP-AD) and Molecular Mechanisms of the Vascular Etiology of AD (M²OVE-AD) consortia. Dr. Ertekin-Taner is the PI of the Florida Consortium for African-American Alzheimer’s Disease Studies (FCA³DS). As a neurologist in the Memory Disorders Clinic at Mayo Clinic in Jacksonville, Florida, Dr. Ertekin-Taner continues to evaluate and manage patients with AD and other dementias and aspires to improve the quality of care that we provide to our patients and their families.

Learning objectives:

Define areas of new neuroscience knowledge and research

Identify Clinicopathologic (CPC) correlations of neurologic disease

Illuminate areas of practice-based improvement within the neurosciences based on advancing scientific research or Practice-based improvement projects.

Speaker Nilufer, M.D., PhD. has no financial relationship to disclose or intentions to discuss off label/investigational use of a commercial product/device.

The Planning Committee members: Nilufer Taner, M.D., PhD., Valerie Fernandez, Linda Gibson and Ruby Ethridge have no relevant financial relationships to disclose.

Mayo Clinic College of Medicine and Science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit is available to Mayo Clinic Staff only.

This program is supported in part by an educational grant from the following company in accordance with ACCME Standards: None